| Literature DB >> 24994917 |
David S Ettinger1, Charles R Handorf1, Mark Agulnik1, Daniel W Bowles1, Justin M Cates1, Mihaela Cristea1, Efrat Dotan1, Keith D Eaton1, Panagiotis M Fidias1, David Gierada1, G Weldon Gilcrease1, Kelly Godby1, Renuka Iyer1, Renato Lenzi1, John Phay1, Asif Rashid1, Leonard Saltz1, Richard B Schwab1, Lawrence N Shulman1, Jeffrey B Smerage1, Marvaretta M Stevenson1, Gauri R Varadhachary1, Jonathan S Zager1, Weining Ken Zhen1, Mary Anne Bergman1, Deborah A Freedman-Cass1.
Abstract
The NCCN Guidelines for Occult Primary tumors provide recommendations for the evaluation, workup, management, and follow-up of patients with occult primary tumors (cancers of unknown primary). These NCCN Guidelines Insights summarize major discussion points of the 2014 NCCN Occult Primary panel meeting. The panel discussed gene expression profiling (GEP) for the identification of the tissue of origin and concluded that, although GEP has a diagnostic benefit, a clinical benefit has not been demonstrated. The panel recommends against GEP as standard management, although 20% of the panel believes the diagnostic benefit of GEP warrants its routine use. In addition, the panel discussed testing for actionable mutations (eg, ALK) to help guide choice of therapy, but declined to add this recommendation.Entities:
Mesh：
Year: 2014 PMID： 24994917 DOI： 10.6004/jnccn.2014.0093
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908